CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical meetings, relating to OLINVYK® (oliceridine) injection, in several core therapeutic areas. Trevena attended the following medical congresses, which also featured presentations on OLINVYK® data:
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
